While the response of the combinational use of these therapeutics was seldom reported, we hypothesize that their combination use might exert a possible synergistic effect via inhibition of the interaction between VEGF and VEGFR, inhibition of VEGF expression in glioblastoma cells, and tumor cell death by interruption of DNA duplication, all in the context of low toxicity. The gene discussed is VEGFA; the disease is glioblastoma.